Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene
Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. | Semantic Scholar
Mechanisms of action of anti-CD20 monoclonal antibodies. Abbreviation:... | Download Scientific Diagram
iLite® CD20 (+) Target
Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma | Journal of Nuclear Medicine
Mechanisms of killing by anti-CD20 monoclonal antibodies - ScienceDirect
AntiCD20+ Agents - Practical Neurology
Antibody drug development: Targeting CD20 and CD3
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
anti-CD20 (Rituximab) - ACE Biolabs Antibody │ Chemical │ Enzyme
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Anti-mouse CD20 | 18B12-derived | InvivoGen
Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy | PNAS
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Oncogene
An Overview of CD20 Monoclonal Antibodies Drugs- CUSABIO
Frontiers | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
CD20 — Wikipédia
Frontiers | Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Characteristics of selected anti-CD20 monoclonal antibodies | Download Table
Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
Brain Sciences | Free Full-Text | Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Anticorps monoclonal anti-CD20 (rituximab) dans les maladies hématologiques et les affections auto-immunes - ScienceDirect
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis | CNS Drugs
Frontiers | Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
The applications of anti-CD20 antibodies to treat various B cells disorders - ScienceDirect
An Overview of CD20 Monoclonal Antibodies Drugs- CUSABIO
The future of anti-CD 20 monoclonal antibodies : are we making progress ? | Semantic Scholar
